<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956148</url>
  </required_header>
  <id_info>
    <org_study_id>CHDIKI1401</org_study_id>
    <nct_id>NCT02956148</nct_id>
  </id_info>
  <brief_title>Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers</brief_title>
  <acronym>LONGPDE10</acronym>
  <official_title>Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington´s Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A (NCT02061722)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHDI Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHDI Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to measure longitudinally the availability of the PDE10A enzyme in
      HDGECs using the radioligand [18F]MNI-659. The study will be a follow-up, examining HDGECs
      from the CHDIKI1201/PET-HD-PDE10A (NCT02061722) study from 18 to 28 months after the initial
      PET measurement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HDGECs will perform 2 study visits: Visit 1 (screening) and Visit 2 (PET analysis
      utilizing the radioligand [18F]MNI-659). There will also be 2 telephone follow ups; one after
      Visit 1 (telephone follow-up after screening) and one after Visit 2, (telephone follow-up
      after PET). Study visits and telephone follow-ups will take place during a maximum of 97
      days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The longitudinal changes of PDE10A enzyme availability in the caudate, putamen, and globus pallidus of Huntington's Disease Gene Expansion Carriers by comparison of the follow-up and initial PET measurements.</measure>
    <time_frame>The follow up PET measurement can be performed from 18 to 28 months after the initial PET measurement that was performed in the CHDIKI/PET-HD-PDE10A Study</time_frame>
    <description>The HDGECs will perform 2 study visits; Visits 1 (screening) and Visit 2 (PET) and 2 telephone follow ups, one after Visit 1 (telephone follow-up after screening) and one after Visit 2, (telephone follow-up after PET) 18 to 28 months after the initial PET measurement conducted in the CHDIKI1201/PET-HD-PDE10A study. An individual subject's participation in this study will last for a maximum of 97 days</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Huntington's Disease</condition>
  <arm_group>
    <arm_group_label>Radioligand [18F]MNI-659</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.
The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radioligand [18F]MNI-659</intervention_name>
    <description>The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.</description>
    <arm_group_label>Radioligand [18F]MNI-659</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have participated in and completed study CHDIKI1201/PET-HD-PDE10A and are capable of
             providing informed consent or have a legal representative authorized to give consent
             on their behalf.

          -  Otherwise healthy according to medical history, no co-morbidity of psychotic
             disorders, physical examination, vital signs and laboratory assessments

          -  Willing to travel to Stockholm (with a companion if requested) for PET examinations

          -  Suitable physically and psychologically to travel to Stockholm and undergo PET
             examinations, as judged by the recruiting Investigator with attention given to
             symptoms of chorea and anxiety

          -  Willing to comply with the use of adequate contraceptive measures

        Exclusion Criteria:

          -  Any disease, condition or concomitant medications that significantly compromises the
             function of the body systems and that, in the opinion of the Investigator might
             interfere with the conduct of the study or the interpretation

          -  Regular use of any medication prohibited by this protocol (selective or non-selective
             PDE inhibitors), with the exception for erectile dysfunction medication, which may be
             temporarily discontinued prior to the PET measurement

          -  History of anaphylactoid or anaphylactic reactions to any allergen including drugs and
             contrast media

          -  History of other neurological condition (including brain surgery, intracranial
             hematoma, stroke/cerebrovascular disorders, epilepsy), co-morbidity of psychiatric
             disorders

          -  Clinically relevant findings in hematological, biochemical testing or 12-lead ECG as
             determined by the evaluating physician

          -  Female subjects who are breast-feeding or have a positive pregnancy test at screening
             or at Visit 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Varrone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Sampaio, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHDI Foundation, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Hallgårde</last_name>
    <phone>+46 (0)46 280 19 17</phone>
    <email>anne.hallgarde@tfscro.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Hansson</last_name>
    <phone>+46 709 13 51 26</phone>
    <email>thomas.hansson@tfscro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Memory Clinic, Rigshopitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorgen Nielsen, MD, PI</last_name>
      <phone>+45 35 45 68 01</phone>
      <email>jnielsen@sund.ku.dk</email>
    </contact>
    <investigator>
      <last_name>Jorgen Nielsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center, Department of Neurology</name>
      <address>
        <city>Leiden</city>
        <zip>K5Q112</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reineke Bos, MD</last_name>
      <phone>+31 715266094</phone>
      <email>R.Bos@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>R.A.C. Roos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oslo, Nevrologisk poliklinikk</name>
      <address>
        <city>Oslo</city>
        <zip>0372 Oslo</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ragnhild Wehus</last_name>
      <phone>+47 23 07 55 80</phone>
      <email>rwehus@ous-hf.no</email>
    </contact>
    <investigator>
      <last_name>Jan Frich, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane Universitetssjukhus Lund, Neurologiska kliniken</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Reimer, RN</last_name>
      <phone>+46 46 17 41 23</phone>
      <email>jan.reimer@med.lu.se</email>
    </contact>
    <investigator>
      <last_name>Hakan Widner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhus, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Wallden, RN</last_name>
      <phone>+46 70 627 41 40</phone>
      <email>tina.wallden-reza-soltani@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Per Svenningsson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Paucar Arce, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dag Nyholm, MD</last_name>
      <phone>+4618-6115038</phone>
      <email>Dag.Nyholm@neuro.uu.se</email>
    </contact>
    <investigator>
      <last_name>Dag Nyholm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2016</study_first_posted>
  <last_update_submitted>November 2, 2016</last_update_submitted>
  <last_update_submitted_qc>November 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

